Saturday, November 21, 10:13 pm IST
Hot Searches:  mukesh ambanisugarforbes rich list
| Feedback
Moneycontrol » News Center » Stocks » Brokerage Recommendations
Sun Pharma an underperformer: Karvy
Published on Mon, Aug 17, 2009 at 10:41   |  Updated at Mon, Aug 17, 2009 at 10:44  |  Source : Moneycontrol.com

Karvy Stock Broking has maintained its underperformer rating on Sun Pharmaceutical Industries with a target price of Rs 1125 in its August 17, 2009 research report.

"Sun Pharma recently received USFDA approval for generic Eloxatin and Imitrex. Eloxatin is 180 day shared exclusivity. 5 players have approval during the exclusivity period. We maintain our EPS estimates for FY 10E and FY 11E but upgrade our multiple to 16x as compared to 15x earlier and upgrade our price target by 6.6 % to Rs 1125 based on 16x FY 2011E. We however continue to maintain Underperformer rating on the stock," says Karvy's research report.


Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click on the attachment......

Attachments : Daily 17-08-09.pdf

Important Links Today:  Leadership Wall    Chat Calendar    The 10 List   
Stock Advice
Anand Rathi Securities
Indiabulls Securities Research
Indiabulls Securities Research
 
 
 

What's your Opinion

WHAT OTHERS LIKE
  • Most Read
  • Most Viewed
©Network 18, 2009. All Rights Reserved